[HTML][HTML] Roxadustat for CKD-related anemia in non-dialysis patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney international …, 2021 - Elsevier
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin… - Kidney …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
[引用][C] Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2021 - cir.nii.ac.jp
Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2021 - profiles.wustl.edu
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2021 - hub.hku.hk
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
Roxadustat for CKD-related Anemia in Non-dialysis Patients.
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2020 - europepmc.org
Methods ANDES was a global Phase 3 randomized study in which adults with stage 3-5
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
[PDF][PDF] Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim, AA Cadena… - 2020 - academia.edu
Methods: ANDES was a global Phase 3 randomized study in which adults with stage 3–5
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
[HTML][HTML] Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2021 - kireports.org
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …
Roxadustat for CKD-related anemia in non-dialysis patients
DW Coyne - 2020 - digitalcommons.wustl.edu
Methods: ANDES was a global Phase 3 randomized study in which adults with stage 3–5
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
[HTML][HTML] Roxadustat for CKD-related Anemia in Non-dialysis Patients
DW Coyne, SD Roger, SK Shin, SG Kim… - Kidney International …, 2021 - ncbi.nlm.nih.gov
Methods ANDES was a global Phase 3 randomized study in which adults with stage 3–5
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …
CKD not on dialysis received roxadustat or placebo. Patients were initially dosed thrice …